Five Recent Deals Show ADCs Aren’t Cooling Off For Summer
While 2024 has seen two buyouts of antibody-drug conjugate specialists with $1bn-plus price tags, the focus on ADCs has continued, accounting for almost half of recent oncology deals.
![summer_cloudsresized.jpg](https://insights.citeline.com/resizer/v2/X54K4DE5ZZIDFLT53TTNLVUEQE.jpg?smart=true&auth=8e2c7f17981dab85d372d55e3dc598647c64102f7b2e2ed1a7b4ccf07f49bc6f&width=700&height=394)
While 2024 has seen two buyouts of antibody-drug conjugate specialists with $1bn-plus price tags, the focus on ADCs has continued, accounting for almost half of recent oncology deals.